Class I Processing-Defective Burkitt's Lymphoma Cells Are Recognized Efficiently by CD4+ EBV-Specific CTLs

Journal of Immunology

Volumn 158, Issue 8, 1997, Pages 3619-3625

  Khanna, Rajiv ^a   Burrows, Scott R ^a   Thomson, Scott A ^a   Moss, Denis J ^a   Cresswell, Peter ^b   Poulsen, Leith M ^a   Cooper, Leanne ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; BURKITT LYMPHOMA; CD4+ T LYMPHOCYTE; CELL CULTURE; CYTOTOXICITY; EPSTEIN BARR VIRUS; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANTIGENS, VIRAL; BURKITT LYMPHOMA; CD4-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MOLECULAR SEQUENCE DATA; TUMOR CELLS, CULTURED;

EID: 0031569518     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Moss, D. J., I. S. Misko, S. R. Burrows, K. Burman, R. McCarthy, and T. B. Sculley. 1988. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 331:719.
2. Rooney, C. M., C. A. Smith, C. Y. C. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1995. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345:9.
3. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169.
4. Murray, R. J., M. G. Kurilla, J. M. Brooks, W. A. Thomas, M. Rowe, E. Kieff, and A. B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176:157.
5. Rooney, C. M., A. B. Rickinson, D. J. Moss, G. M. Lenoir, and M. A. Epstein. 1984. Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. Int. J. Cancer 34:339.
6. Khanna, R., S. R. Burrows, and D. J. Moss. 1995. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59:387.
7. Khanna, R., S. R. Burrows, V. Argaet, and D. J. Moss. 1994. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int. Immunol. 6:639.
8. Rowe, M., R. Khanna, C. A. Jacob, V. Argaet, A. Kelly, S. Powis, M. Belich, D. Croom Carter, S. Lee, S. R. Burrows, D. J. Moss, and A. B. Rickinson. 1995. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol. 25:1374.
9. Misko, I. S., T. D. Soszynski, R. G. Kane, and J. H. Pope. 1984. Factors influencing the human cytotoxic T-cell response to autologous lymphoblastoid cell lines in vitro. Clin. Immunol. Immunopathol 32:285.
10. + virus-specific cytotoxic T cells which recognize Epstein-Barr virus lytic antigen BHRF1. Virology 219:489.
11. Salter, R. D., and P. Cresswell. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant T×B cell hybrid. EMBO J. 5:943.
12. Denzin, L. K., N. F. Robbins, C. Carboy Newcomb, and P. Cresswell. 1994. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity 1:595.
13. Rosenberg, S. A., E. A. Grimm, M. McGrogan, M. Doyle, E. Kawasaki, K. Koths, and D. F. Mark. 1984. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 223:1412.
14. Wang, A., S. D. Lu, and D. F. Mark. 1984. Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science 224:1431.
15. Khanna, R., C. A. Jacob, S. R. Burrows, M. G. Kurilla, E. Kieff, I. S. Misko, and D. J. Moss. 1991. Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T-cells. Immunology 74:504.
16. Khanna, R., C. A. Jacob, S. R. Burrows, and D. J. Moss. 1993. Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection. J. Immunol. Methods 164:41.
17. Burrows, S. R., S. J. Rodda, A. Suhrbier, H. M. Geysen, and D. J. Moss. 1992. The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur. J. Immunol. 22:191.
18. Boyle, D. B., B. E. Coupar, and G. W. Both. 1985. Multiple-cloning-site plasmids for the rapid construction of recombinant poxviruses. Gene 35:169.
19. Khanna, R., S. R. Burrows, D. J. Moss, and S. L. Silins. 1996. Peptide transporter (TAP-1/2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for CTL control of EBV-associated malignancies. J. Virol. 70:5357.
20. Burrows, S. R., J. Gardner, R. Khanna, T. Steward, D. J. Moss, S. Rodda, and A. Suhrbier. 1994. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J. Gen. Virol. 75:2489.
21. Sculley, T. B., A. Apolloni, R. Stumm, D. J. Moss, N. Mueller-Lantzsch, I. S. Misko, and D. A. Cooper. 1989. Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 is altered in cell lines containing B-type virus. Virology 171:401.
22. Sample, J., and E. Kieff. 1990. Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes. J. Virol. 64:1667.
23. Denzin, L. K., and P. Cresswell. 1995. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 82:155.
24. Sherman, M. A., D. A. Weber, and P. E. Jensen. 1995. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 3:197.
25. Riberdy, J. M., J. R. Newcomb, M. J. Surman, J. A. Barbosa, and P. Cresswell. 1992. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 360:474.
26. Sette, A., S. Southwood, D. O'Sullivan, F. C. Gaeta, J. Sidney, and H. M. Grey. 1992. Effect of pH on MHC class II-peptide interactions. J. Immunol. 148:844.
27. Thorley-Lawson, D. A. 1980. The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell. J. Immunol. 124:745.
28. Thorley-Lawson, D. A., L. Chess, and J. L. Strominger. 1977. Suppression of in vitro Epstein-Barr virus infection: a new role for adult human T lymphocytes. J. Exp. Med. 146:495.
29. Hasler, F., H. G. Bluestein, N. J. Zvaifler, and L. B. Epstein. 1983. Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation. J. Exp. Med. 157: 173.
30. Andersson, U., S. Britton, M. De Ley, and G. Bird. 1983. Evidence for the ontogenic precedence of suppressor T-cell functions in the human neonate. Eur. J. Immunol. 13:6.
31. Cresswell, P. 1994. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12:259.
32. Jacobson, S., R. P. Sekaly, C. L. Jacobson, H. F. McFarland, and E. O. Long. 1989. HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J. Virol. 63:1756.
33. + cells infected with a vaccinia virus encoding influenza type a nucleoprotein by class II restricted T cells. Immunol. Lett. 36:305.
34. Weiss, S., and B. Bogen. 1991. MHC class II-restricted presentation of intracellular antigen. Cell 64:767.
35. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer 58:69.
36. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA 91:9461.
37. - T cells: tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161: 1122.
38. Kern, D. E., J. P. Klarnet, M. C. Jensen, and P. D. Greenberg. 1986. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J. Immunol. 136: 4303.
39. Ostrand Rosenberg, S., C. A. Roby, and V. K. Clements. 1991. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J. Immunol. 147:2419.